Monday, February 11, 2019
GlobalMed Technologies Company, a leader in international medical device manufacturing and sales, announced today an exciting new partnership with DermaConcepts™, a top U.S. distributor of innovative aesthetic products and trainings. The agreement involves DermaConcepts in the upcoming Q2 2019 launch of GlycoAla®, as the official exclusive U.S. distributor.
GlycoAla is the only photodynamic gel containing hyaluronic acid, a natural moisturizer, that also utilizes an advanced glycosphere nanoparticle delivery system for enhanced stability and skin absorption. GlycoAla is activated by red light during a single session or 3 treatments spread over a 12-week period to help reduce the appearance of pore size, fine lines, and wrinkles, and resulting in a brighter and more hydrated-looking skin tone. GlycoAla does not require a recovery period or have side effects typically associated with more aggressive techniques.
Commenting on the agreement, Sanders Ergas, President and CEO at GlobalMed Technologies Company, said, "We are really excited about working with DermaConcepts. Our companies share the same vision of being first to market with advanced and efficacious products for skin care professionals to share with their clientele. We are completely convinced, after much due diligence that, as a top U.S. distributor of scientifically developed skin care products, DermaConcepts is the right choice to help us launch GlycoAla to physicians and medical spas in the United States."
Robert and Carol Trow, CEO and President of DermaConcepts, respectively, added, "GlycoAla represents an extraordinary, state of the art product that offers material, sustainable and measurable results for patients. The novel properties of GlycoAla combined with a powerful LED device yields unprecedented, non-invasive results that dramatically improve the appearance of fine lines, wrinkles and pore size in as little as three treatments. We are excited to be able to offer this groundbreaking cosmetic treatment."
